Latest Insider Transactions at Alector, Inc. (ALEC)
This section provides a real-time view of insider transactions for Alector, Inc. (ALEC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Alector, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Alector, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 22
2023
|
Terrance Mcguire Director |
SELL
Other acquisition or disposition
|
Indirect |
598,533
-52.11%
|
-
|
|
Aug 22
2023
|
Terrance Mcguire Director |
BUY
Other acquisition or disposition
|
Direct |
6,429
+10.47%
|
-
|
|
Aug 22
2023
|
Polaris Venture Management Co. Vi, L.L.C. |
SELL
Other acquisition or disposition
|
Direct |
98,533
-100.0%
|
-
|
|
Aug 22
2023
|
Polaris Venture Management Co. Vi, L.L.C. |
BUY
Other acquisition or disposition
|
Direct |
98,533
+50.0%
|
-
|
|
Aug 22
2023
|
Polaris Venture Management Co. Vi, L.L.C. |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-4.22%
|
-
|
|
Jul 15
2023
|
Richard H Scheller |
BUY
Grant, award, or other acquisition
|
Direct |
8,541
+16.18%
|
-
|
|
Jun 14
2023
|
Elizabeth A. Garofalo |
BUY
Grant, award, or other acquisition
|
Direct |
26,250
+42.37%
|
-
|
|
Jun 14
2023
|
Paula Hammond |
BUY
Grant, award, or other acquisition
|
Direct |
26,250
+42.37%
|
-
|
|
Jun 14
2023
|
Richard H Scheller |
BUY
Grant, award, or other acquisition
|
Direct |
26,250
+42.37%
|
-
|
|
Jun 14
2023
|
Louis J Lavigne Jr |
BUY
Grant, award, or other acquisition
|
Direct |
26,250
+42.37%
|
-
|
|
Jun 14
2023
|
Kristine Yaffe |
BUY
Grant, award, or other acquisition
|
Direct |
26,250
+42.37%
|
-
|
|
Jun 14
2023
|
David M. Wehner |
BUY
Grant, award, or other acquisition
|
Direct |
26,250
+24.63%
|
-
|
|
Jun 14
2023
|
Terrance Mcguire Director |
BUY
Grant, award, or other acquisition
|
Direct |
26,250
+35.09%
|
-
|
|
Jun 14
2023
|
Tillman U. Gerngross |
BUY
Grant, award, or other acquisition
|
Direct |
26,250
+0.98%
|
-
|
|
Jun 02
2023
|
Gary Romano Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,617
-2.5%
|
$15,702
$6.9 P/Share
|
|
Jun 02
2023
|
Marc Grasso Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,050
-3.05%
|
$6,300
$6.9 P/Share
|
|
Jun 02
2023
|
Sara Kenkare Mitra President and Head of R&D |
SELL
Open market or private sale
|
Direct |
4,092
-2.17%
|
$24,552
$6.9 P/Share
|
|
Jun 02
2023
|
Arnon Rosenthal Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,255
-0.32%
|
$31,530
$6.9 P/Share
|
|
Mar 17
2023
|
Arnon Rosenthal Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,186
-0.91%
|
$91,116
$6.22 P/Share
|
|
Mar 03
2023
|
Arnon Rosenthal Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,990
+2.51%
|
-
|
|
Mar 02
2023
|
Gary Romano Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,238
-3.0%
|
$25,904
$8.32 P/Share
|
|
Mar 02
2023
|
Marc Grasso Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,291
-3.62%
|
$10,328
$8.32 P/Share
|
|
Mar 02
2023
|
Sara Kenkare Mitra President and Head of R&D |
SELL
Open market or private sale
|
Direct |
10,124
-5.1%
|
$80,992
$8.32 P/Share
|
|
Mar 02
2023
|
Arnon Rosenthal Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,849
-0.36%
|
$46,792
$8.32 P/Share
|
|
Dec 02
2022
|
Gary Romano Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,145
-1.95%
|
$17,160
$8.71 P/Share
|
|
Nov 16
2022
|
Polaris Venture Management Co. Vi, L.L.C. |
SELL
Other acquisition or disposition
|
Direct |
98,533
-100.0%
|
-
|
|
Nov 16
2022
|
Polaris Venture Management Co. Vi, L.L.C. |
BUY
Other acquisition or disposition
|
Direct |
98,533
+50.0%
|
-
|
|
Nov 16
2022
|
Polaris Venture Management Co. Vi, L.L.C. |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-4.05%
|
-
|
|
Nov 16
2022
|
Terrance Mcguire Director |
BUY
Other acquisition or disposition
|
Indirect |
111,666
+41.66%
|
-
|
|
Nov 16
2022
|
Terrance Mcguire Director |
SELL
Other acquisition or disposition
|
Indirect |
598,533
-52.02%
|
-
|
|
Nov 16
2022
|
Terrance Mcguire Director |
BUY
Other acquisition or disposition
|
Direct |
6,429
+22.36%
|
-
|
|
Oct 01
2022
|
Marc Grasso Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,702
+50.0%
|
-
|
|
Oct 01
2022
|
Gary Romano Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,047
+15.4%
|
-
|
|
Oct 01
2022
|
Robert King Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,576
+3.77%
|
-
|
|
Oct 01
2022
|
Sara Kenkare Mitra President and Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
80,365
+28.83%
|
-
|
|
Oct 01
2022
|
Arnon Rosenthal Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
179,169
+9.88%
|
-
|
|
Sep 02
2022
|
Gary Romano Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,177
-2.36%
|
$21,770
$10.62 P/Share
|
|
Sep 02
2022
|
Robert King Chief Development Officer |
SELL
Open market or private sale
|
Direct |
176
-0.03%
|
$1,760
$10.62 P/Share
|
|
Jun 16
2022
|
Elizabeth A. Garofalo |
BUY
Grant, award, or other acquisition
|
Direct |
9,459
+50.0%
|
-
|
|
Jun 16
2022
|
Tillman U. Gerngross |
BUY
Grant, award, or other acquisition
|
Direct |
9,459
+0.36%
|
-
|
|
Jun 16
2022
|
Paula Hammond |
BUY
Grant, award, or other acquisition
|
Direct |
9,459
+50.0%
|
-
|
|
Jun 16
2022
|
Louis J Lavigne Jr |
BUY
Grant, award, or other acquisition
|
Direct |
9,459
+50.0%
|
-
|
|
Jun 16
2022
|
Terrance Mcguire Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,459
+37.32%
|
-
|
|
Jun 16
2022
|
David M. Wehner |
BUY
Grant, award, or other acquisition
|
Direct |
9,459
+14.89%
|
-
|
|
Jun 16
2022
|
Kristine Yaffe |
BUY
Grant, award, or other acquisition
|
Direct |
9,459
+50.0%
|
-
|
|
Jun 16
2022
|
Richard H Scheller |
BUY
Grant, award, or other acquisition
|
Direct |
9,459
+50.0%
|
-
|
|
Jun 02
2022
|
Robert King Chief Development Officer |
SELL
Open market or private sale
|
Direct |
177
-0.03%
|
$1,416
$8.71 P/Share
|
|
May 27
2022
|
Gary Romano Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
92,250
+50.0%
|
-
|
|
Mar 01
2022
|
Robert King Chief Development Officer |
SELL
Open market or private sale
|
Direct |
287
-0.05%
|
$4,305
$15.57 P/Share
|
|
Jan 03
2022
|
Sara Kenkare Mitra President and Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
118,000
+41.67%
|
-
|